Objective. Human papillomavirus (HPV), particularly HPV16, is a causative agent for 25% of head and neck squamous cell cancer, including laryngeal squamous cell cancer (LSCC). HPV-positive (HPV1ve) patients, particularly those with oropharyngeal SCC, have improved prognosis. For LSCC patients, this remains to be established. The goal was to determine stage and survival outcomes in LSCC in the context of HPV infection.
L aryngeal squamous cell cancer (LSCC), the largest subgroup of head and neck cancers, share common risk factors to include smoking and alcohol consumption. The human papilloma virus (HPV) is a causative agent for some head and neck squamous cell cancers (HNSCCs) 1, 2 and an independent risk factor for oropharyngeal HNSCC. [3] [4] [5] A systematic review of 5046 patients with HNSCC reported an overall prevalence of HPV infection of 25.9% and concurs with a more recent meta-analysis of 5681 HNSCC. 6 The prevalence of HPV infection was significantly higher among patients with oropharyngeal SCC (35.6%) than among those with oral (23.5%) or laryngeal (24.0%) SCC. 7 Approximately 95% of these HNSCC subgroups contain high-risk HPV type 16 (HPV16) genomic DNA sequences. 8 Its contribution to neoplastic progression is predominantly through the action of the viral oncoproteins E6 and E7. 9 Expression of these proteins is sufficient for the immortalization of primary human epithelial cells and induction of histologic atypia characteristic of preinvasive HPV-associated squamous intraepithelial lesions. 10 The contribution of HPV genotypes to HNSCC pathogenesis is of clinical significance. HPV-positive (HPV1ve) patients, particularly those with oropharyngeal cancer, have improved prognosis. Patients whose tumors test positive for HPV have at least half the risk of death from HNSCC and respond better to treatment than those who test negative. 3, 11 This includes selection of patients for organ preservation therapy, which may be more successful in patients with HPV1ve HNSCC. 12 Also, a recent study found that poorer survival outcomes for African Americans (AA) versus Caucasian Americans (CA) with oropharyngeal tumors was attributable to racial differences in the prevalence of HPV1ve tumors. HPV positivity was higher in CA (34%) when compared with AA (4%), and HPV-negative (HPV-ve) AA and CA patients had similar survival outcomes. 13 Therefore, the therapeutic implications of an HPV1ve diagnosis are an important area of investigation, with mounting evidence for future clinical trials designed specifically for patients with HPV1ve or HPV-ve HNSCC stratified according to HPV status. 3 For LSCC, survival outcomes based on overall prevalence of HPV, especially race-based prevalence, remain to be established. The goal of this study was to evaluate the stage at diagnosis and survival outcomes in LSCC in the context of HPV infection.
Materials and Methods Cohort
The retrospective study cohort of 79 primary LSCC was examined for a set of 21 variables to include 8 histopathology factors 14 15 The ACE-27 categorizes specific diseases into 1 of 3 grades: grade 1 (mild), grade 2 (moderate), and grade 3 (severe), based on organ decompensation and prognostic impact. An overall comorbidity score (none = 0, mild = 1, moderate = 2, or severe = 3) is assigned based on the highest ranked/graded single ailment. 16 If 2 or more moderate-grade ailments occur in a case, the overall comorbidity score is designated as severe.
Access to care for this cohort is defined as the availabil- This study was approved by the Henry Ford Health System Institutional Review Board.
DNA Extraction
Whole 5-mm tissue sections or microdissected LSCC lesions and adjacent normal tissue when present were processed for DNA extraction as previously described. 17
HPV16 Detection by Real-Time Quantitative Polymerase Chain Reaction
Tumor HPV DNA concentrations were measured using a realtime quantitative PCR (qRT-PCR) system. Real-time PCR reactions were set up in a reaction volume of 20 mL using the TaqMan Universal Master Mix II with UNG (Applied Biosystems, Foster City, California). Specific primers and probes were designed to amplify a housekeeping gene, bglobin 18 (to standardize the input DNA), and the E6 region of HPV16. 19 The primers and probes used were as follows: bglobin: forward 5#-GTGCACCTGACTCCTGAGGAGA-3#, reverse 5#-CCTTGATACCAACCTGCCCAG-3#, 6FAM-5#-AAGGTGAACGTGGATGAAGTTGGTGG-3#-TAMRA; HPV16 E6 region: forward 5#-GAGAACTGCAATGTTT-CAGGACC-3#, reverse 5#-TGTATAGTTGTTTGCAGCTC-TGTGC-3#, 6FA-M-5#-CAGGAGCGACCCAGAAAGTTA-CCACAGTT-3#T-AMRA. DNA amplifications were carried out in a 96-well reaction plate format in a PE Applied Biosystems 7500HT Sequence Detector (Applied Biosystems). HPV viral copy number was determined using the CaSki cell line genomic DNA reported to contain an integrated HPV16 genome (about 600 copies per cell). Multiple water blanks and HPV16 positive controls (HPV1ve HNSCC specimens) were included in every run. Both the HPV and b-globin PCR reactions were carried out in duplicate.
qRT-PCR Data Analysis
CaSki cell line (American Type Culture Collection [ATCC], Manassas, Virginia) genomic DNA is known to have 600 copies/genome equivalent (6.6 pg of DNA/genome). Standard curves were developed for HPV16 viral copy number using serial dilutions of 50 ng, 5 ng, 0.5 ng, 0.05 ng, and 0.005 ng of DNA. Using the same serial dilutions, standard curves were also developed for the b-globin housekeeping gene (2 copies/genome). This additional step allowed for relative quantification of the input DNA level and attribution of the final quantity as the number of viral copies/genome/cell. 20 The cutoff value for HPV16 positive status of 0.03 (3 HPV genome copy/100 cells) by qRT-PCR was based on interrogation of formalin-fixed DNA from a separate cohort of 31 HNSCC previously typed using the Linear Array HPV Genotyping test (Roche, Indianapolis, Indiana) and conventional PCR ( Table 1) . The lowest qRT-PCR value for samples that were positive by the linear array and conventional PCR was 0.0305, illustrated for sample T30 in Table 1 .
Statistical Analysis
x 2 or Fisher exact test was used to test the association of HPV1ve with the other risk factors (race, stage, gender, age, smoking, alcohol, treatment, health insurance type). Kaplan-Meier and log-rank tests were used to compare survival time difference between patients with and without HPV. A multivariable analysis would be considered to test HPV effects on survival adjusting for the other clinical risk factors if an HPV effect was detected (P \ .05) at the univariate analysis level. To assess outcomes from this study for comparison to published data, ad hoc analyses were conducted to examine survival difference among categories, particularly for HPV status, race, gender, treatment, and insurance type.
Results
Of the 79 primary LSCC, 45 were CA, 32 (41%) were AA, 1 was Hispanic, and 1 was Arab American; 38 were early stage, 40 late stage, and 1 unknown stage. There were 60 men and 19 women. These patients were categorized into 4 treatment groups of surgery alone (no radiation or chemotherapy [no R/C]: 22 HPV-ve, 4 HPV1ve), radiation only (R: 30 HPV-ve, 15
HPV1ve), radiation plus chemotherapy (R1C: 4 HPV-ve, 1 HPV1ve), and chemotherapy only (C: 1 HPV1ve). Although HPV is often associated with a basaloid histologic morphology, it was not noted for any of the cases in this cohort. Other cohort characteristics including age, smoking status, alcohol use, HPV status, insurance type, and laryngeal subsite localization are presented in Table 2 . The laryngeal subsites were determined by careful assessment of pathology and clinical notes. There were 6 cases in which the tumor overlapped more than 1 site within the larynx ( patients was not available because of insufficient DNA (1 AA male and 1 Arab American male). CA had higher HPV prevalence (33%) than did AA LSCC (16%; P = .058).
HPV1ve status was significantly associated with gender (P = .016); 34% (20/58) of men were HPV1ve versus 5% (1/19) of women. HPV and insurance type were significantly correlated (P = .001). The Medicare group had more HPV-ve (28/ 56) than HPV1ve patients (6/21); the Blue Cross insurance group had only HPV1ve patients (6/6). There was no correlation between HPV status and stage (P = .797).
There was no significant association between overall survival, HPV status, and race. HPV1ve LSCC patients had a median survival of 79.68 months compared with 75 months for HPV-ve patients (P = .35; Figure 1 ). There was no statistically significant difference in survival among LSCC racial groups based on HPV status (P = .6; Figure 2 ).
There was no correlation between HPV status, race, stage, and treatment. HPV was correlated with gender (P = .02). Survival appeared better for HPV1ve men when compared with HPV-ve men (Figure 3) .
There was no difference in survival between the treated (R, R1C, or C) and the surgery-alone group (P = .39; Figure 4 ). Insurance payor type was attributed to 86% of the cohort; 14% lacked insurance information. Survival and insurance payor type showed significant correlation (P = .039; Figure 5 ). Patients with private insurance (HAP/Blue Cross, reference) had better survival when compared with patients with Medicare (P = .034) or other HMO groups (P = .036). There was no difference in survival between the Medicare and other HMO groups.
Kaplan-Meier plots by race and insurance type show small but interesting differences (not shown); AA and CA 
Discussion
The prevalence of oncogenic HPV types in LSCC has a wide distribution, ranging from 0% 21 to 69%, 22 and indicates some controversy as to whether HPV is implicated in laryngeal cancer. Torrente et al 23 believed the prevalence in LSCC varies so widely because of differences in methods of HPV detection as well as selection bias due to small sample size or poor quality of the cancer specimen. qRT-PCR is a more reliable method for quantifying viral load with a minimal chance for contamination due to isolated wells. Other advantages of qRT-PCR include the ability to give a quantity of input template, absence of post-PCR processing, and allowance for relative quantitation of multiple target templates. 24 In a pooled meta-analysis study 7 of 5046 head and neck cancers, of which 1435 were laryngeal cancers, HPV DNA was identified in 24% of tested laryngeal tumors (95% confidence interval [CI], 21.8-26.3) using conventional PCR-based assays. HPV16 was the main genotype detected with differences in prevalence among anatomic sites, with a prevalence of 17% in the laryngeal cases. 7 In our study, HPV16, detected by qRT-PCR, was present in 27% of the cohort, supporting a role for HPV in LSCC. 21, 22 HPV1ve patients with HNSCC, particularly those with oropharyngeal cancer, 25 have improved prognosis; however, for LSCC, this remains to be established. In this LSCC cohort, HPV1ve patients had a slightly longer survival than did HPV-ve patients, but this did not reach statistical significance, likely because of sample size limitations. The significant association between HPV positivity and male gender (P = .016) is likely due to the higher incidence of HNSCC in men (3:1 ratio). The significant correlation between HPV and insurance type (P = .001) points to interesting observations among insurance groups. Of particular interest is the finding that the Medicare group had more HPV-ve (58% vs 32%) HNSCC. In a separate, much larger HNSCC cohort from our group (oral personal communication from Dr Maria J. Worsham), older patients in the over-65-years group were 55% less likely to be HPV1ve than those in the 50 group (odds ratio, 0.45; 95% CI, 0.22, 0.89; P = .021).
The prevalence of HPV in CA was 33% as compared with 16% in AA LSCC (P = .058) and is much higher than that reported by Settle et al 25 for oropharyngeal SCC (34% CA vs 4% AA). It is important to note that Settle et al 25 had 28 AA patients, only 1 of whom was HPV16 positive by conventional PCR. We found no differences in survival based on HPV status and race.
There was no correlation between HPV status and clinical stage (early vs late), concurring with the findings of Baumann et al. 26 There were about equal numbers of early-stage (n = 38) and late-stage (n = 40) LSCC, with approximately equal numbers of HPV1ve cases in both groups. There was also no association between HPV status and treatment.
In an oropharyngeal cancer cohort, Worden et al 27 reported that a greater proportion of men than women were HPV1ve and that female gender was significantly associated with poor disease-specific survival. In our study, the proportion of HPV1ve LSCC was nearly 7-fold higher in men (20 of 58, 34%) than in female patients (1 of 19, 5%; P = .016), and while survival plots show HPV1ve men with better overall survival as compared with HPV-ve men, in women small sample sizes were a limiting factor.
There were no differences in survival between HPV1ve and HPV-ve patients. HPV1ve LSCC had a median survival of 79.68 months compared with 75 months for HPV-ve patients (P = .35) Among LSCC racial groups, HPV1ve CA showed better survival when compared with HPV-ve CA (Figure 2) ; HPV-ve CA and AA had similar survival. Within the AA group, differences in survival between HPV-ve and HPV1ve patients were not discernable because of smaller numbers of AA cases (Figure 2) .
Settle et al 25 demonstrated better overall survival for HPV1ve over HPV-ve HNSCC receiving combined chemotherapy and radiation mainly due to improved overall survival in the oropharyngeal subgroup. We found no significant difference in survival between LSCC patients who received radiation treatment alone and those who received surgery alone (no radiation or chemotherapy). Nevertheless, survival plots indicate that HPV1ve patients who received chemoradiation had better survival when compared with HPV-ve LSCC. Also, HPV1ve CA patients displayed better survival than HPV1ve AA patients; however, this was not significant and likely due to the small numbers in the HPV1ve AA group (n = 5).
Lack of health insurance is a barrier to accessing optimal health care for HNSCC. Also, insurance type often dictates access to prevention and early detection, including regular health care checkups and seeking care for symptomatic disease (ie, the delay between first seeking care and definitive diagnosis). 28 Kwok et al 29 studied the impact of health insurance status on the survival of HNSCC patients and found that patients with Medicaid/uninsured and Medicare disability had significantly lower overall survival compared with patients with private insurance. We also observed improved survival outcomes for those with private insurance (HAP/Blue Cross) when compared with Medicare patients (P = .034). Also, CA patients with HAP and Blue Cross appeared to have better survival when compared with the Medicare group, while CA and AA Medicare patients had similar survival.
Studies in the past have shown that HPV status and smoking history are inversely correlated in HNSCC. 30, 31 Baumann et al 26 confirmed this finding in an early-stage laryngeal cancer cohort in which 67% of HPV1ve tumors were in patients who never smoked versus 22% of HPV-ve patients with no smoking history. Most patients in our cohort had a history of smoking (95%). Of the 4 patients who never smoked, only 1 was HPV1ve.
Despite the strikingly better survival of patients with HPV1ve tumors, even when adjusted for smoking, this correlation does not seem to hold true in the larynx. Larger multiethnic LSCC cohorts are needed to more clearly delineate HPV-related stage and survival outcomes across ethnicities. Identification of such LSCC patient subsets should result in more optimized treatment approaches to improve overall survival and quality of life.
Acknowledgments
Drs Stephen and Worsham had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. 
